TY - JOUR
T1 - Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer
T2 - Comparison of Current Guidelines and Recommendations
AU - Persad, Raj
AU - Lamm, Donald
AU - Brausi, Maurizio
AU - Soloway, Mark
AU - Palou, Joan
AU - Böhle, Andreas
AU - Colombel, Marc
AU - Akaza, Hideyuki
AU - Buckley, Roger
AU - Witjes, J. Alfred
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008/10
Y1 - 2008/10
N2 - Context: The guidelines of the European Association of Urology (EAU), the First International Consultation on Bladder Tumors (FICBT), the National Comprehensive Cancer Network (NCCN), and the American Urological Association (AUA) all provide an excellent evidence-based background for the management of non-muscle invasive bladder cancer (NMIBC). Although there are areas of consensus among the four guidelines, their recommendations vary with respect to important issues surrounding NMIBC. Objective: To provide community urologists with practical and unified guidance on the management of NMIBC through a comprehensive review of current influencing guidelines. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), was convened in October 2006 to review current literature surrounding the management of NMIBC as well as the current clinical practice guidelines of the EAU, the FICBT, the NCCN and the AUA. Following the inaugural meeting in October 2006, the IBCG met on three subsequent occasions (March 2007, September 2007, and March 2008) to critically analyze and compare the EAU, FICBT, NCCN, and AUA guidelines. Evidence synthesis: The IBCG critically analyzed and summarized the EAU, FICBT, NCCN, and AUA guidelines and identified the key similarities and differences in their recommendations. Conclusions: Established areas of consensus among the four guidelines include the importance of transurethral resection of the bladder tumour (TURBT) and an immediate, postoperative dose of chemotherapy (agent optional) in all patients with NMIBC, as well as the benefit of adjuvant bacillus Calmette-Guérin (BCG) therapy in high-risk disease. However, the four guideline recommendations vary with regard to the following important issues: (1) the definitions of low-, intermediate-, and high-risk disease, and (2) the appropriate management and follow-up of patients in each of these risk categories. Furthermore, there is currently no consensus on the definition and appropriate management strategies for primary intravesical treatment failures among the four guidelines.
AB - Context: The guidelines of the European Association of Urology (EAU), the First International Consultation on Bladder Tumors (FICBT), the National Comprehensive Cancer Network (NCCN), and the American Urological Association (AUA) all provide an excellent evidence-based background for the management of non-muscle invasive bladder cancer (NMIBC). Although there are areas of consensus among the four guidelines, their recommendations vary with respect to important issues surrounding NMIBC. Objective: To provide community urologists with practical and unified guidance on the management of NMIBC through a comprehensive review of current influencing guidelines. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), was convened in October 2006 to review current literature surrounding the management of NMIBC as well as the current clinical practice guidelines of the EAU, the FICBT, the NCCN and the AUA. Following the inaugural meeting in October 2006, the IBCG met on three subsequent occasions (March 2007, September 2007, and March 2008) to critically analyze and compare the EAU, FICBT, NCCN, and AUA guidelines. Evidence synthesis: The IBCG critically analyzed and summarized the EAU, FICBT, NCCN, and AUA guidelines and identified the key similarities and differences in their recommendations. Conclusions: Established areas of consensus among the four guidelines include the importance of transurethral resection of the bladder tumour (TURBT) and an immediate, postoperative dose of chemotherapy (agent optional) in all patients with NMIBC, as well as the benefit of adjuvant bacillus Calmette-Guérin (BCG) therapy in high-risk disease. However, the four guideline recommendations vary with regard to the following important issues: (1) the definitions of low-, intermediate-, and high-risk disease, and (2) the appropriate management and follow-up of patients in each of these risk categories. Furthermore, there is currently no consensus on the definition and appropriate management strategies for primary intravesical treatment failures among the four guidelines.
KW - American Urological Association guidelines
KW - Bacillus Calmette-Guérin
KW - European Association of Urology guidelines
KW - First International Consultation on Bladder Tumors recommendations
KW - Intravesical chemotherapy
KW - Management of non-muscle invasive bladder cancer
KW - National Comprehensive Cancer Network guidelines
KW - Transurethral resection of the bladder tumour
KW - Treatment failures
UR - http://www.scopus.com/inward/record.url?scp=51349136972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51349136972&partnerID=8YFLogxK
U2 - 10.1016/j.eursup.2008.07.007
DO - 10.1016/j.eursup.2008.07.007
M3 - Review article
AN - SCOPUS:51349136972
VL - 7
SP - 637
EP - 650
JO - European Urology, Supplements
JF - European Urology, Supplements
SN - 1569-9056
IS - 10
ER -